Prevention of hepatocellular carcinoma

HPB

Volumn 7, Issue 1, 2005, Pages 16-25

  Kew, Michael C ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; ALPHA INTERFERON; CHLOROPHYLL; CYANOGINOSIN; GLUCOSINOLATE; GLUTATHIONE TRANSFERASE; GLYCYRRHIZIC ACID; HEPATITIS B VACCINE; HEPATITIS C VACCINE; ISOTHIOCYANIC ACID DERIVATIVE; OLTIPRAZ; ORAL CONTRACEPTIVE AGENT; POLYPRENOIC ACID; STEROID; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BLOOD ANALYSIS; BLOOD DONOR; CANCER INCIDENCE; CANCER PREVENTION; CIGARETTE SMOKING; CLINICAL TRIAL; DIETARY INTAKE; DRUG MECHANISM; FOOD CONTAMINATION; FOOD INTAKE; FOOD PREFERENCE; GEOGRAPHIC DISTRIBUTION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFERIOR CAVA VEIN OBSTRUCTION; INSULIN RESISTANCE; IRON INTAKE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIMARY PREVENTION; RISK FACTOR; SECONDARY PREVENTION;

EID: 15844426930     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1080/13651820410024030     Document Type: Review

References (62)

1. Ferlay J, Bray J, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. Version 1.0. IARC CancerBase No. 5. International Agency for Research on Cancer. Lyon: IARC Press, 2001.
2. WHO Mortality Database. World Health Statistics Annuals, 1998.
3. Bosch FX, Ribes J. The epidemiology of primary liver cancer: global epidemiology. In: Tabor E, ed. Viruses and liver cancer. Amsterdam: Elsevier, 2002:1-16.
4. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85.
5. Farber E. Approaches to cancer prevention: introduction and perspective. Proc Am Assoc Cancer Res 1988;29:527-8.
6. Beasley RP, Hwang L-Y, Lin CC, Chien CS. Hepatocellular carcinoma and HBV: a prospective study of 22,707 men in Taiwan. Lancet 1981;22:1129-33.
7. Stevens CE, Szmuness W. Vertical transmission of hepatitis B and neonatal hepatitis B. In: Bianchi L, Gerok W, Sickinger K, Stalder GA, eds. Virus and the liver. Lancaster, UK: MTP Press, 1980:71-4.
8. Botha JA, Ritchie MJJ, Dusheiko GM, Mouton HWK, Kew MC. Hepatitis B virus carrier state in Black children in Ovamboland: role of perinatal and horizontal infection. Lancet 1984;2:1209-12.
9. Kew MC. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Vir Hepatit Rev 1998;4: 259-69.
10. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
11. Kew MC. The role of cirrhosis in hepatocarcinogenesis. In: Bannasch P, Keppler D, Weber G, eds. Liver cell carcinoma. Dordrecht: Kluwer Academic Publishers, 1989:37-46.
12. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002;17:471-81.
13. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. Nature Rev 2003;3: 321-9.
14. Sudakin DL. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J Toxicol Clin Toxicol 2003;41: 195-204.
15. 1 and hepatitis B virus in hepatocarcinogenesis. Liver Int 2003;23: 1-5.
16. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and non-cirrhotic patients with hereditary hemochromatosis. N Engl J Med 1985;313:1256-62.
17. Isaacson C, Seftel HC, Keeley KJ, Bothwell TH. Siderosis in the Bantu: the relationship between iron overload and cirrhosis. J Lab Clin Med 1981;58:845-53.
18. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Roualt TA, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-6.
19. Yu SZ, Chen G. Blue green algae toxins and liver cancer. China J Cancer Res 1994;6:9-17.
20. Zhou TL, Yu SZ. Laboratory study on the relationship between drinking water and hepatoma: quantitative evaluation using GGT method. China J Prev Med 1990;234:203-5.
21. Chang M-H. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003;23:309-14.
22. Chang W-H, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. The effect of universal hepatitis B vaccination on hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284:3040-2.
23. Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after largescale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003;12:57-9.
24. Kane MA. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:2-3.
25. Kew MC, Francois G, Lavanchy D, et al. Prevention of hepatitis C virus infection. J Med Virol 2004 (in press).
26. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ, Wild PC. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: a basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002;17:S441-S448.
27. Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995;10:674-82.
28. Egner PA, Wang J-B, Zhu YR, Zhang BC, Wu Y, Zhang QN, et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk of liver cancer. Proc Natl Acad Sci U S A 2001;98:14601-6.
29. Dashwood R, Negishi T, Hayatsu H, Breinholt V, Hendricks J, Bailey G. The importance of using pure chemical in (anti) mutagenicity studies: chlorophyllin as a case in point. Murat Res 1998;399:245-53.
30. 1: complex formation with the carcinogen. Chem Res Toxicol 1995;8:506-14.
31. Kamat JP, Boloor KK, Devasgayan TP. Chlorophyllin as an effective anti-oxidant against the membrane damage in vitro and ex vivo. Biochim Biophys Acta 2000;1487:113-27.
32. Morel F, Fardel O, Meyer DJ, Langouet S, Gilmore KS, Meunier B, et al. Preferential increase of glutathione-S-transferase class α transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene and dithiolethiones. Cancer Res 1993;53:231-4.
33. Itoh K, Wakabayashi N, Kotoh H, Ishii T, Igarashi K, Engel JD, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the aminoterminal Neh2 domain. Genes Dev 1999;13:76-86.
34. 1 metabolism in human hepatocytes in primary culture. Cancer Res 1995;55: 5574-9.
35. Jacobson LP, Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997;6:257-65.
36. Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol 2001;16:1329-35.
37. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996;334:1561-7.
38. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999;340:1046-7.
39. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and the prevention of cancer: a global perspective. Washington, DC: American Institute for Cancer Research, 1997.
40. Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acd Sci USA 1997;94: 10367-72.
41. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, et al. Hepatitis C genotypes and the risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
42. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer D, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110: 1107-19.
43. Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with hepatitis B and C viruses. Dig Liv Dis 2003;35:297-305.
44. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon-α treatment in Chinese patients with chronic hepatitis B infection: the effect of hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-45.
45. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-81.
46. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
47. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, et al. Long-term interferon for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001;16:406-15.
48. Ikeda A, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-30.
49. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol Suppl 2003;237:47-51.
50. Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002;47:170-6.
51. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon-β prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomised study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32.
52. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001;134:963-7.
53. Melen K, Keskinen P, Lehtonen A, Julkinen I. Interferon-induced gene expression and signalling in human hepatoma cell lines. J Hepatol 2000;33:764-72.
54. Yamashita Y, Koike K, Takaoki M, Matsuda S. Suppression of HBsAg production in PLC/PRF/5 human hepatoma cell line by interferons. Microbiol Immunol 1988;32:1119-26.
55. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001;34:593-602.
56. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by hepatitis B virus: a pilot study. Cancer 1998;82:827-35.
57. Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26:535-9.
58. Kimura M, Watanabe H, Abe T. Selective activation of extrathymic T cells in the liver by glycyrrhizin. Biotherapy 1992; 5:167-76.
59. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
60. van Rossum TGJ, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Glycyrrhizin as a potential treatment for chronic hepatitis C: a double-blind, randomised, placebo-controlled phase 1/2 trial. Aliment Pharmacol Ther 1998;12:199-205.
61. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002;62(Suppl 1):94-100.
62. Tarao K, Takemiya S, Tamai S, Sugimasa Y, Ohkawa S, Akaike M, et al. Relationship between the recurrence of hepatocellular carcinoma and serum aminotransferase levels in hepatectomised patients with hepatitis C virus-associated cirrhosis and hepatocellular carcinoma. Cancer 1997;79: 688-94.